LGD-6972 to be a foundational program for Metavant, a new company formed by Roivant to pursue the development of innovative therapies for cardiometabolic diseases SAN DIEGO (March 6, 2018) – Ligand…
Read More
Poxel to receive upfront payment of $35 million (approximately €28 million), potential future development and regulatory milestone payments and sales-based payments of up to $600 million (approximately €486 million), and…